- Email: [email protected]
Device for thawing frozen transfusion material and method therefore
iv Trunsfus. Sci. Vol. 15. No. I
5239113 SUBSTITUTED BETA-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS AND INTERMEDIATES THEREOF Phillipe R Bovy, Joseph Rico, Thomas E Rogers, Foe S Tjoeng, Jeffery Zablocki assigned to Monsanto Company; G D Searle & Co Novel substituted beta amino acid derivatives are provided which inhibit platelet aggregation and intermediates thereof. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.
5243833 DEVICE FOR THAWING FROZEN TRANSFUSION MATERIAL AND METHOD THEREFORE Philip H Coelho, Terry Wolf assigned to Instacool Inc of North America A method and device for thawing pouches of frozen transfusion material including a membrane which provides a barrier within an interior of the device with the membrane receiving the pouches of frozen material therewithin. The interior of the device includes a sump having thawing fluid stored therein and maintained at a constant target temperature which is to be achieved by the frozen transfusion material to be thawed. The pouch of material to be thawed, after placement within the membrane, is exposed (through the membrane) to hydrostatic forces associated with the fluid in the sump collapsing the membrane on the pouch while pulsating jets impinge indirectly upon the pouch through the membrane. In this way, as the contents within the pouch thaw, circulation of the fluid within the pouch occurs for more rapid realization of the target temperature for the fluid within the pouch.
5246832 PLATELET ANALYSIS IN WHOLE BLOOD Alan Michelson, Anita S Kestin assigned to University of Massachusetts Medical Center
Method of determining, in a blood sample, containing unwashed platelets and fibrinogen, the state of thrombin reactivity of the platelets by adding thrombin tothe sample in the presence of an agent for inhibiting fibrin polymerization, and then detecting activated platelets.
5248506 SYNTHETIC, PLASMA-FREE, TRANSFUSIBLE STORAGE MEDIUM FOR RED BLOOD CELLS AND PLATELETS Stein Holme, William A Heaton assigned to American National Red Cross The invention is a sterile, plasma-free storage medium for blood components including red blood cells and for platelets processed separately or together. The red cell storage medium includes a physiologically compatible, aqueous electrolyte solution. In one liter of this electrolyte solution there is between about 3.0 grams and about 25.0 grams of dextrose, between about 3.0 grams and about 6.0 grams of sodium citrate, and between about 2.0 grams and about 4.2 grams of sodium bicarbonate. The red cell storage medium is isotonic and has a pH in a range of between about 6.8 and about 1.4. The red cell storage medium is capable of storing and preserving red cells for at least 49 days.
5248666 METHODS FOR INHIBITING NEOPLASTIC CELL PROLIFERATION USING PLATELET FACTOR 4 Daniel Twardzik, George J Todaro assigned to Oncogen Novel polypeptide compositions are provided which inhibit human tumor cell growth, which may or may not stimulate autophosphorylation of pp6src and induce the release of a 52 kD polypeptide from neoplastic cells. Individual polypeptides may be isolated from mammalian blood platelets by selected extraction and purification procedures, may be synthesized or produced by hybrid DNA technology.
5239113 SUBSTITUTED BETA-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS AND INTERMEDIATES THEREOF Phillipe R Bovy, Joseph Rico, Thomas E Rogers, Foe S Tjoeng, Jeffery Zablocki assigned to Monsanto Company; G D Searle & Co Novel substituted beta amino acid derivatives are provided which inhibit platelet aggregation and intermediates thereof. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.
5243833 DEVICE FOR THAWING FROZEN TRANSFUSION MATERIAL AND METHOD THEREFORE Philip H Coelho, Terry Wolf assigned to Instacool Inc of North America A method and device for thawing pouches of frozen transfusion material including a membrane which provides a barrier within an interior of the device with the membrane receiving the pouches of frozen material therewithin. The interior of the device includes a sump having thawing fluid stored therein and maintained at a constant target temperature which is to be achieved by the frozen transfusion material to be thawed. The pouch of material to be thawed, after placement within the membrane, is exposed (through the membrane) to hydrostatic forces associated with the fluid in the sump collapsing the membrane on the pouch while pulsating jets impinge indirectly upon the pouch through the membrane. In this way, as the contents within the pouch thaw, circulation of the fluid within the pouch occurs for more rapid realization of the target temperature for the fluid within the pouch.
5246832 PLATELET ANALYSIS IN WHOLE BLOOD Alan Michelson, Anita S Kestin assigned to University of Massachusetts Medical Center
Method of determining, in a blood sample, containing unwashed platelets and fibrinogen, the state of thrombin reactivity of the platelets by adding thrombin tothe sample in the presence of an agent for inhibiting fibrin polymerization, and then detecting activated platelets.
5248506 SYNTHETIC, PLASMA-FREE, TRANSFUSIBLE STORAGE MEDIUM FOR RED BLOOD CELLS AND PLATELETS Stein Holme, William A Heaton assigned to American National Red Cross The invention is a sterile, plasma-free storage medium for blood components including red blood cells and for platelets processed separately or together. The red cell storage medium includes a physiologically compatible, aqueous electrolyte solution. In one liter of this electrolyte solution there is between about 3.0 grams and about 25.0 grams of dextrose, between about 3.0 grams and about 6.0 grams of sodium citrate, and between about 2.0 grams and about 4.2 grams of sodium bicarbonate. The red cell storage medium is isotonic and has a pH in a range of between about 6.8 and about 1.4. The red cell storage medium is capable of storing and preserving red cells for at least 49 days.
5248666 METHODS FOR INHIBITING NEOPLASTIC CELL PROLIFERATION USING PLATELET FACTOR 4 Daniel Twardzik, George J Todaro assigned to Oncogen Novel polypeptide compositions are provided which inhibit human tumor cell growth, which may or may not stimulate autophosphorylation of pp6src and induce the release of a 52 kD polypeptide from neoplastic cells. Individual polypeptides may be isolated from mammalian blood platelets by selected extraction and purification procedures, may be synthesized or produced by hybrid DNA technology.